CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. CytomX is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its Probody® technology platform that could meaningfully improve outcomes for cancer patients. Its proprietary and unique Probody technology platform is designed to enable “conditional activation” of antibody- and cytokine-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation.

CytomX’s robust and differentiated pipeline comprises numerous Probody therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engaging bispecifics, and cytokine therapies. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. CytomX is headquartered in South San Francisco, California.